Jacques Bouget1, Frédéric Balusson1, Maxime Maignan2, Laure Pavageau3, Pierre-Marie Roy4, Karine Lacut5, Lucie-Marie Scailteux1, Emmanuel Nowak5, Emmanuel Oger1. 1. Univ Rennes, CHU Rennes, EA 7449 [Pharmacoepidemiology and Health Services Research] REPERES, Rennes, France. 2. Emergency Department, University Hospital, Grenoble, France. 3. Emergency Department, University hospital, Nantes, France. 4. Emergency Department, University hospital, Angers, France. 5. CIC 1412, Université de Bretagne Loire, Université de Brest, INSERM, CHRU de Brest, Brest, France.
Abstract
AIMS: The objective was to compare major bleeding risk of direct oral anticoagulants (DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication, using real-world data. METHODS: A population-based prospective cohort study, using the French national health data system (SNIIRAM), identified 47 469 adults living within 5 well-defined geographical areas, who were new users of oral anticoagulants in the period 2013-2015: 20 205 VKA users, 19 579 rivaroxaban users, 4225 dabigatran users and 3460 apixaban users. From all emergency departments within these areas, clinical data for all adults referred for bleeding was collected and medically validated. The databases were linked for common key variables. The main outcome measure was major bleeding: intracranial haemorrhage, major gastrointestinal bleeding and other major bleeding events. Hazard ratios were derived from adjusted Cox proportional hazard models. We used propensity score weighting as a sensitivity analysis, with separate analyses according to indications (atrial fibrillation or venous thromboembolism). RESULTS: Compared to VKAs, high and low-dose DOACs were associated with a reduced risk of intracranial haemorrhage (adjusted hazard ratio 0.55, 95% confidence interval 0.37-0.82 and 0.54, 0.26-1.12 respectively), and a reduced risk of other major bleeding events (0.41, 0.29-0.58 and 0.41, 0.22-0.79 respectively), irrespective of duration and indication. Neither DOAC dose evidenced any significant difference from VKAs in terms of risk of major gastrointestinal bleeding. CONCLUSION: There is a clear benefit of using DOACs with regard to intracranial haemorrhage. The study provides new insight into major gastrointestinal and other major bleeding events.
AIMS: The objective was to compare major bleeding risk of direct oral anticoagulants (DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication, using real-world data. METHODS: A population-based prospective cohort study, using the French national health data system (SNIIRAM), identified 47 469 adults living within 5 well-defined geographical areas, who were new users of oral anticoagulants in the period 2013-2015: 20 205 VKA users, 19 579 rivaroxaban users, 4225 dabigatran users and 3460 apixaban users. From all emergency departments within these areas, clinical data for all adults referred for bleeding was collected and medically validated. The databases were linked for common key variables. The main outcome measure was major bleeding: intracranial haemorrhage, major gastrointestinal bleeding and other major bleeding events. Hazard ratios were derived from adjusted Cox proportional hazard models. We used propensity score weighting as a sensitivity analysis, with separate analyses according to indications (atrial fibrillation or venous thromboembolism). RESULTS: Compared to VKAs, high and low-dose DOACs were associated with a reduced risk of intracranial haemorrhage (adjusted hazard ratio 0.55, 95% confidence interval 0.37-0.82 and 0.54, 0.26-1.12 respectively), and a reduced risk of other major bleeding events (0.41, 0.29-0.58 and 0.41, 0.22-0.79 respectively), irrespective of duration and indication. Neither DOAC dose evidenced any significant difference from VKAs in terms of risk of major gastrointestinal bleeding. CONCLUSION: There is a clear benefit of using DOACs with regard to intracranial haemorrhage. The study provides new insight into major gastrointestinal and other major bleeding events.
Authors: Craig I Coleman; Matthias Antz; Kevin Bowrin; Thomas Evers; Edgar P Simard; Hendrik Bonnemeier; Riccardo Cappato Journal: Curr Med Res Opin Date: 2016-09-20 Impact factor: 2.580
Authors: Ana Ruigómez; Gunnar Brobert; Kiliana Suzart-Woischnik; Luis Alberto García-Rodríguez Journal: Pharmacoepidemiol Drug Saf Date: 2018-06-27 Impact factor: 2.890
Authors: Daniel M Witt; Thomas Delate; Elaine M Hylek; Nathan P Clark; Mark A Crowther; Francesco Dentali; Walter Ageno; Kerri D Martinez; David A Garcia Journal: Thromb Res Date: 2013-10-17 Impact factor: 3.944
Authors: Mary S Vaughan Sarrazin; Michael Jones; Alexander Mazur; Elizabeth Chrischilles; Peter Cram Journal: Am J Med Date: 2014-08-12 Impact factor: 4.965
Authors: John D Seeger; Katsiaryna Bykov; Dorothee B Bartels; Krista Huybrechts; Kristina Zint; Sebastian Schneeweiss Journal: Thromb Haemost Date: 2015-10-08 Impact factor: 5.249